by Gonzalo Payan | Apr 10, 2026
It is with great honor and pleasure that we report that Dr. Scott L. Friedman has joined MAX BioPharma’s Scientific Advisory Board. Dr. Friedman is Dean for Collaborative Research & Partnerships, Director of the Institute for Liver Research, and Chief Emeritus of...by Gonzalo Payan | Mar 12, 2026
MAX BioPharma and Technomark Life Sciences announced their collaboration in the development of MAX BioPharma’s oxysterol drug candidate, Oxy210, targeting metabolic dysfunction-associated steatohepatitis (MASH). As a strategic lead investor, Technomark is...by Gonzalo Payan | Aug 7, 2025
MAX BioPharma, Inc. and Revilico, Inc. announced their collaboration in studying the mechanisms of action, performing lead optimization, and identifying the molecular targets of MAX BioPharma’s oxysterol-based drug candidates using a state-of-the-art,...by Gonzalo Payan | Aug 4, 2025
MAX BioPharma Reports on Oxy210’s Inhibition of Hepatic Expression of Senescence-Associated, Pro-Fibrotic, and Pro-Inflammatory Genes in Mice During Development of MASH and in Hepatocytes In Vitro. Read the full study...by Gonzalo Payan | Jun 14, 2025
MAX BioPharma reports on the Inhibition of Atherosclerosis in Hyperlipidemic Mice and Inflammatory Responses of Vascular Cells by its Oxysterol Drug Candidate, Oxy210 Paper available from https://pubmed.ncbi.nlm.nih.gov/39404395/